In addition, Majid et al. [28] demonstrated that dacomitinib, an irreversible tyrosine kinase inhibitor, exhibits stronger anti-tumor efficacy than single-targeted ERBB inhibitors in PDAC. Here, EGFR is linked to neoplasm.